Concert Pharmaceuticals Inc (CNCE)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Roger D. Tung
Employees:
60
99 HAYDEN AVENUE, SUITE 500, LEXINGTON, MA 02421
781-860-0045

Concert Pharmaceuticals, Inc. develops novel small molecule drugs for the treatment of autoimmune diseases. Lead product candidate is CTP-543, which is in Phase III clinical trial for treatment of alopecia areata, a serious autoimmune dermatological condition. Company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.

Data derived from most recent annual or quarterly report
Market Cap 222.699 Million Shares Outstanding36.329 Million Avg 30-day Volume 503.121 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.51
Price to Revenue3.7956 Debt to Equity0.0 EBITDA-93.001 Million
Price to Book Value1.6148 Operating Margin-274.93940000000003 Enterprise Value13.73 Million
Current Ratio7.61 EPS Growth-0.135 Quick Ratio7.353
1 Yr BETA 1.2832 52-week High/Low 6.88 / 2.57 Profit Margin-291.9903
Operating Cash Flow Growth7.1652 Altman Z-Score-4.0213 Free Cash Flow to Firm -30.347 Million
View SEC Filings from CNCE instead.

View recent insider trading info

Funds Holding CNCE (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding CNCE BETA

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Events (8k)

  • 8-K: filed on 2022-08-04:
    Item 2.02: Results of Operations and Financial Condition
    Item 8.01: Other Events
  • 8-K: filed on 2022-06-13:
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 8.01: Other Events
  • 8-K: filed on 2022-06-03:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-23:
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-12:
    Item 8.01: Other Events
  • 8-K: filed on 2022-05-05:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-03-03:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-11-09:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-11-08:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-08-05:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    HUTT PETER BARTON

    • Director
    29,488 2022-06-09 1

    ALDRICH RICHARD

    • Director
    635,787 2022-06-09 2

    JAEGER WILFRED E

    • Director
    21,525 2022-06-09 1

    AUCHINCLOSS THOMAS G

    • Director
    34,025 2022-06-09 2

    VAN HEEK CHRISTI

    • Director
    49,054 2022-06-09 2

    HOEILAND JESPER

    • Director
    21,525 2022-06-09 1

    TUNG ROGER D CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    1,127,794 2022-02-15 4

    CASSELLA JAMES V CHIEF DEVELOPMENT OFFICER

    • Officer
    189,822 2022-02-14 4

    STUART NANCY CHIEF OPERATING OFFICER

    • Officer
    284,737 2022-02-14 3

    BECKER MARC A. CHIEF FINANCIAL OFFICER

    • Officer
    139,011 2022-02-14 4

    MUNSIE JEFFREY A CHIEF LEGAL OFFICER

    • Officer
    103,197 2022-02-14 3

    BARRETT RONALD W

    • Director
    15,375 2021-06-10 0

    LYNCH RYAN PAO

    • Officer
    18,059 2019-08-15 0

    BVF PARTNERS L P/IL

    BIOTECHNOLOGY VALUE FUND L P

    BIOTECHNOLOGY VALUE FUND II LP

    BIOTECHNOLOGY VALUE TRADING FUND OS LP

    BVF PARTNERS OS LTD.

    BVF INC/IL

    LAMPERT MARK N

    • 10% Owner
    • SEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSES
    No longer subject to file 2019-06-10 0

    WIERENGA WENDALL

    • Director
    0 2018-06-14 0

    FITZGERALD MEGHAN

    • Director
    0 2018-06-14 0

    HERSCHA LYNETTE GENERAL COUNSEL

    • Officer
    46,318 2018-03-31 0

    BECKER MARC CFO, PFO

    • Officer
    0 2018-01-04 0

    SILVERMAN ROBERT SENIOR VP, GENERAL COUNSEL

    • Officer
    50,307 2017-03-09 0

    DAWS D. RYAN CHIEF FINANCIAL OFFICER

    • Officer
    0 2017-01-04 0

    MCGOWAN PAULINE VP, FINANCE

    • Officer
    0 2016-01-07 0

    JAEGER WILFRED E

    THREE ARCH MANAGEMENT III LLC

    THREE ARCH MANAGEMENT IV, L.L.C.

    • Director
    75,292 2015-12-14 0

    SCHUHSLER HELMUT

    • Director
    0 2015-06-11 0

    THREE ARCH MANAGEMENT III LLC

    THREE ARCH PARTNERS III LP

    THREE ARCH ASSOCIATES III LP

    WAN MARK A

    JAEGER WILFRED E

    • Director
    • 10% Owner
    No longer subject to file 2014-11-18 0

    THREE ARCH MANAGEMENT IV, L.L.C.

    JAEGER WILFRED E

    WAN MARK A

    THREE ARCH PARTNERS IV LP

    THREE ARCH ASSOCIATES IV LP

    • Director
    • 10% Owner
    569,427 2014-11-18 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    AUCHINCLOSS THOMAS G - Director

    2022-06-13 16:13:11 -0400 2022-06-09 A 16,400 a 34,025 direct 4.1958 -4.662 26.3403 26.3403 31 -4.662 6

    ALDRICH RICHARD - Director

    2022-06-13 16:12:13 -0400 2022-06-09 A 16,400 a 358,500 direct 4.1958 -4.662 26.3403 26.3403 31 -4.662 6

    ALDRICH RICHARD - Director

    2022-06-13 16:12:13 -0400 2022-06-09 A 22,410 a 22,410 direct

    VAN HEEK CHRISTI - Director

    2022-06-13 16:17:37 -0400 2022-06-09 A 16,400 a 42,051 direct 4.1958 -4.662 26.3403 26.3403 31 -4.662 6

    VAN HEEK CHRISTI - Director

    2022-06-13 16:17:37 -0400 2022-06-09 A 7,003 a 7,003 direct

    JAEGER WILFRED E - Director

    2022-06-13 16:16:35 -0400 2022-06-09 A 16,400 a 21,525 direct 4.1958 -4.662 26.3403 26.3403 31 -4.662 6

    HOEILAND JESPER - Director

    2022-06-13 16:14:26 -0400 2022-06-09 A 16,400 a 21,525 direct 4.1958 -4.662 26.3403 26.3403 31 -4.662 6

    HUTT PETER BARTON - Director

    2022-06-13 16:15:36 -0400 2022-06-09 A 16,400 a 29,488 direct 4.1958 -4.662 26.3403 26.3403 31 -4.662 6

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    CONCERT PHARMACEUTICALS INC CNCE 2022-08-05 22:15:04 UTC 1.782 0.538 2200000
    CONCERT PHARMACEUTICALS INC CNCE 2022-08-05 21:45:03 UTC 1.782 0.538 2200000
    CONCERT PHARMACEUTICALS INC CNCE 2022-08-05 21:15:03 UTC 1.782 0.538 2200000
    CONCERT PHARMACEUTICALS INC CNCE 2022-08-05 20:45:04 UTC 1.782 0.538 2200000
    CONCERT PHARMACEUTICALS INC CNCE 2022-08-05 20:15:05 UTC 1.782 0.538 2200000
    CONCERT PHARMACEUTICALS INC CNCE 2022-08-05 19:45:04 UTC 1.782 0.538 2200000
    CONCERT PHARMACEUTICALS INC CNCE 2022-08-05 19:15:05 UTC 1.782 0.538 2200000
    CONCERT PHARMACEUTICALS INC CNCE 2022-08-05 18:45:04 UTC 1.782 0.538 2200000
    CONCERT PHARMACEUTICALS INC CNCE 2022-08-05 18:15:03 UTC 1.782 0.538 2200000
    CONCERT PHARMACEUTICALS INC CNCE 2022-08-05 17:45:04 UTC 1.782 0.538 2200000
    CONCERT PHARMACEUTICALS INC CNCE 2022-08-05 17:15:04 UTC 1.782 0.538 2200000
    CONCERT PHARMACEUTICALS INC CNCE 2022-08-05 16:45:05 UTC 1.782 0.538 2200000
    CONCERT PHARMACEUTICALS INC CNCE 2022-08-05 16:15:05 UTC 1.782 0.538 2200000
    CONCERT PHARMACEUTICALS INC CNCE 2022-08-05 15:45:04 UTC 1.782 0.538 2200000
    CONCERT PHARMACEUTICALS INC CNCE 2022-08-05 15:15:03 UTC 1.782 0.538 2200000
    CONCERT PHARMACEUTICALS INC CNCE 2022-08-05 14:45:04 UTC 1.782 0.538 2200000
    CONCERT PHARMACEUTICALS INC CNCE 2022-08-05 14:15:04 UTC 1.782 0.538 2200000
    CONCERT PHARMACEUTICALS INC CNCE 2022-08-05 13:45:05 UTC 1.6776 0.6424 2200000
    CONCERT PHARMACEUTICALS INC CNCE 2022-08-05 13:15:04 UTC 1.6776 0.6424 2200000
    CONCERT PHARMACEUTICALS INC CNCE 2022-08-05 12:45:05 UTC 1.6776 0.6424 2200000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    Elevate your investments